{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:53:23Z","timestamp":1785700403117,"version":"3.56.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.encep.2025.10.010","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:40:09Z","timestamp":1771360809000},"page":"369-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Coprescription of antipsychotics and benzodiazepines at hospital discharge"],"prefix":"10.1016","volume":"52","author":[{"given":"Maxime","family":"Demourgues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Richaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Thiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Debruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Queuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2025.10.010_bib0190","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/YCO.0000000000000787","article-title":"Psychopharmacology of agitation in acute psychotic and manic episodes","volume":"35","author":"Stetson","year":"2022","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.encep.2025.10.010_bib0195","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5811\/westjem.2011.9.6866","article-title":"The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup","volume":"13","author":"Wilson","year":"2012","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.encep.2025.10.010_bib0200","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jemermed.2017.10.011","article-title":"Evidence-based review of pharmacotherapy for acute agitation. Part 1: Onset of efficacy","volume":"54","author":"Zun","year":"2018","journal-title":"J Emerg Med"},{"key":"10.1016\/j.encep.2025.10.010_bib0205","first-page":"CD003079","article-title":"Benzodiazepines for psychosis-induced aggression or agitation","volume":"12","author":"Zaman","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.encep.2025.10.010_bib0210","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/0269881114541013","article-title":"Re-examining the role of benzodiazepines in the treatment of schizophrenia: A systematic review","volume":"29","author":"Sim","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.encep.2025.10.010_bib0215","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.euroneuro.2013.03.001","article-title":"Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: A meta-analysis and Cochrane review of randomized controlled trials","volume":"23","author":"Dold","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.encep.2025.10.010_bib0220","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0447.2012.01835.x","article-title":"Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment","volume":"125","author":"L\u00e4ngle","year":"2012","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.encep.2025.10.010_bib0225","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.encep.2025.10.010_bib0230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archgenpsychiatry.2009.175","article-title":"National trends in psychotropic medication polypharmacy in office-based psychiatry","volume":"67","author":"Mojtabai","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.encep.2025.10.010_bib0235","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/XEB.0000000000000082","article-title":"Prevalence of multiple antipsychotic use and associated adverse effects in Australians with mental illness","volume":"14","author":"Westaway","year":"2016","journal-title":"Int J Evid Based Healthc"},{"key":"10.1016\/j.encep.2025.10.010_bib0240","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: Systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.encep.2025.10.010_bib0245","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1017\/S1041610217001934","article-title":"Antipsychotic polypharmacy in older Australians","volume":"30","author":"Kalisch Ellett","year":"2018","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.encep.2025.10.010_bib0250","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2025.10.010_bib0255","first-page":"1885","article-title":"Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice","volume":"11","author":"Dell\u2019Osso","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.encep.2025.10.010_bib0260","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/appi.ajp.2015.15050618","article-title":"Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: An observational follow-up study","volume":"173","author":"Tiihonen","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2025.10.010_bib0265","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.therap.2018.08.001","article-title":"What is pharmacoepidemiology? Definition, methods, interest and clinical applications","volume":"74","author":"Montastruc","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.encep.2025.10.010_bib0270","unstructured":"IRDES. Donn\u00e9es de cadrage\u00a0: L\u2019h\u00f4pital\u00a0: nombre de lits, journ\u00e9es et dur\u00e9e moyenne de s\u00e9jour. IRDES n.d. https:\/\/www.irdes.fr\/enseignement\/chiffres-et-graphiques\/hopital\/nombre-de-lits-journees-et-durees-moyennes-de-sejour.html (accessed July 10, 2024)."},{"key":"10.1016\/j.encep.2025.10.010_bib0275","unstructured":"Rapport d\u2019activit\u00e9 2022 - CH Charles Perrens.pdf n.d."},{"key":"10.1016\/j.encep.2025.10.010_bib0280","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12603-011-0015-7","article-title":"Association between benzodiazepines and recurrent falls: A cross-sectional elderly population-based study","volume":"15","author":"Rossat","year":"2011","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.encep.2025.10.010_bib0285","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00002512-200825010-00007","article-title":"Benzodiazepines and injurious falls in community dwelling elders","volume":"25","author":"Pariente","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.encep.2025.10.010_bib0290","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pharma.2011.10.002","article-title":"Relationship between benzodiazepines use and falls in the elderly: A multicenter study in three geriatric centers of a university hospital","volume":"70","author":"Uhart","year":"2012","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.encep.2025.10.010_bib0295","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0740-5472(91)90024-5","article-title":"Pharmacologic aspects of benzodiazepine tolerance and dependence","volume":"8","author":"Busto","year":"1991","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.encep.2025.10.010_bib0300","doi-asserted-by":"crossref","first-page":"g5205","DOI":"10.1136\/bmj.g5205","article-title":"Benzodiazepine use and risk of Alzheimer's disease: Case-control study","volume":"349","author":"Billioti de Gage","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.encep.2025.10.010_bib0305","doi-asserted-by":"crossref","first-page":"e6231","DOI":"10.1136\/bmj.e6231","article-title":"Benzodiazepine use and risk of dementia: Prospective population based study","volume":"345","author":"Billioti de Gage","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.encep.2025.10.010_bib0310","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/14740338.2015.1014796","article-title":"Is there really a link between benzodiazepine use and the risk of dementia?","volume":"14","author":"Billioti de Gage","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.encep.2025.10.010_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-015-0305-4","article-title":"The benzodiazepine-dementia disorders link: Current state of knowledge","volume":"30","author":"Pariente","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.encep.2025.10.010_bib0320","unstructured":"\u00c9tat des lieux de la consommation des benzodiaz\u00e9pines - Point d\u2019Information - ANSM: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 n.d. https:\/\/archive.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Etat-des-lieux-de-la-consommation-des-benzodiazepines-Point-d-Information (accessed January 8, 2024)."},{"key":"10.1016\/j.encep.2025.10.010_bib0325","doi-asserted-by":"crossref","first-page":"17m11982","DOI":"10.4088\/JCP.17m11982","article-title":"Access to psychotropic medication via prescription is associated with choice of psychotropic medication as suicide method: A retrospective study of 27,876 suicide attempts","volume":"79","author":"Brown","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2025.10.010_bib0330","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1017\/ipm.2019.25","article-title":"Limiting psychotropic medication prescription on discharge from psychiatric inpatient care: a possible suicide intervention?","volume":"37","author":"Cleary","year":"2020","journal-title":"Ir J Psychol Med"},{"key":"10.1016\/j.encep.2025.10.010_bib0335","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1527-3458.2004.tb00023.x","article-title":"Preclinical and clinical pharmacology of cyamemazine: Anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome","volume":"10","author":"Bourin","year":"2004","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.encep.2025.10.010_bib0340","unstructured":"Richaud A, Panes A, Diallo G, Tournier M. D\u00e9prescription des benzodiaz\u00e9pines chez les patients adultes trait\u00e9s au Centre Hospitalier Charles Perrens (Bordeaux, France) \u00c9tat des lieux et facteurs de non r\u00e9introduction entre 2016 et 2022 2023."},{"key":"10.1016\/j.encep.2025.10.010_bib0345","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00406-018-0966-3","article-title":"Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors: A population-based study","volume":"270","author":"Panes","year":"2020","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.encep.2025.10.010_bib0350","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Guidelines for the pharmacotherapy of schizophrenia in adults","volume":"62","author":"Remington","year":"2017","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.encep.2025.10.010_bib0355","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.4103\/0019-5545.196973","article-title":"Clinical practice guidelines for management of schizophrenia","volume":"59","author":"Grover","year":"2017","journal-title":"Indian J Psychiatry"},{"key":"10.1016\/j.encep.2025.10.010_bib0360","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bcp.14947","article-title":"Community-based pharmacists\u2019 role in deprescribing: A systematic review","volume":"88","author":"Bu\u017ean\u010di\u0107","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.encep.2025.10.010_bib0365","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s11096-022-01449-w","article-title":"Implementation of pharmacist-led deprescribing in collaborative primary care settings","volume":"44","author":"Trenaman","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.encep.2025.10.010_bib0370","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4140\/TCP.n.2023.506","article-title":"The effect of pharmacist-initiated deprescribing interventions in older people: A narrative review of randomized controlled trials","volume":"38","author":"Nguyen","year":"2023","journal-title":"Sr Care Pharm"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700626000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700626000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:28:22Z","timestamp":1785698902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700626000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0013700626000035"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2025.10.010","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coprescription of antipsychotics and benzodiazepines at hospital discharge","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2025.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 L'Enc\u00e9phale, Paris.","name":"copyright","label":"Copyright"}]}}